Serologic and Immunohistochemical Prognostic Biomarkers of Cutaneous Malignancies

Overview

Journal Arch Dermatol Res

Specialty Dermatology

Date 2007 Jan 16

PMID 17221215

Citations 14

Authors

Jochen Utikal

Dirk Schadendorf

Selma Ugurel

Affiliations

Soon will be listed here.

Abstract

Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.

Citing Articles

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.

Hoefsmit E, Vollmy F, Rozeman E, Reijers I, Versluis J, Hoekman L Cancer Res Commun. 2023; 3(4):672-683.

PMID: 37089863 PMC: 10117404. DOI: 10.1158/2767-9764.CRC-23-0015.

Significance of 5--Cysteinyldopa as a Marker for Melanoma.

Wakamatsu K, Fukushima S, Minagawa A, Omodaka T, Hida T, Hatta N Int J Mol Sci. 2020; 21(2).

PMID: 31936623 PMC: 7013534. DOI: 10.3390/ijms21020432.

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma.

Kruckel A, Moreira A, Frohlich W, Schuler G, Heinzerling L BMC Cancer. 2019; 19(1):207.

PMID: 30845981 PMC: 6407264. DOI: 10.1186/s12885-019-5384-z.

Current position of TNF-α in melanomagenesis.

Nenu I, Tudor D, Filip A, Baldea I Tumour Biol. 2015; 36(9):6589-602.

PMID: 26279161 DOI: 10.1007/s13277-015-3639-0.

Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.

Vihinen P, Tervahartiala T, Sorsa T, Hansson J, Bastholt L, Aamdal S Cancer Immunol Immunother. 2014; 64(2):173-80.

PMID: 25319807 PMC: 11029364. DOI: 10.1007/s00262-014-1620-1.

References

Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch P, Zelger B . Metallothionein - overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer. 2006; 94(6):835-41. PMC: 2361379. DOI: 10.1038/sj.bjc.6603028. View

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso S . Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006; 98(7):472-82. DOI: 10.1093/jnci/djj103. View

Klemke C, Goerdt S, Schrama D, Becker J . New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges. 2006; 4(5):395-406. DOI: 10.1111/j.1610-0387.2006.05982.x. View

Fecker L, Geilen C, Tchernev G, Trefzer U, Assaf C, Kurbanov B . Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 2006; 126(6):1366-71. DOI: 10.1038/sj.jid.5700192. View

Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A . Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg. 2006; 59(9):961-8. DOI: 10.1016/j.bjps.2006.01.022. View

Curtin J, Busam K, Pinkel D, Bastian B . Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24(26):4340-6. DOI: 10.1200/JCO.2006.06.2984. View

Koseki S, Aoki T, Ansai S, Hozumi Y, Mitsuhashi Y, Kondo S . An immunohistochemical study of E-cadherin expression in human squamous cell carcinoma of the skin: relationship between decreased expression of E-cadherin in the primary lesion and regional lymph node metastasis. J Dermatol. 1999; 26(7):416-22. DOI: 10.1111/j.1346-8138.1999.tb02019.x. View

Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V . S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999; 17(6):1891-6. DOI: 10.1200/JCO.1999.17.6.1891. View

Rodriguez-Rodriguez L, Sancho-Torres I, Gibbon D, Watelet L, Mesonero C . CD44-9v and CD44-10v are potential molecular markers for squamous cell carcinoma of the vulva. J Soc Gynecol Investig. 2000; 7(1):70-5. DOI: 10.1016/s1071-5576(99)00045-3. View

10.

Petter G, Haustein U . Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma. Dermatol Surg. 2000; 26(6):521-30. DOI: 10.1046/j.1524-4725.2000.99181.x. View

11.

Jury C, McAllister E, Mackie R . Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol. 2000; 143(2):269-74. DOI: 10.1046/j.1365-2133.2000.03650.x. View

12.

Boyano M, Gardeazabal J, Bilbao J, Canavate M, Galdeano A, Izu R . Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer. 2000; 83(7):847-52. PMC: 2374688. DOI: 10.1054/bjoc.2000.1402. View

13.

Kraehn G, Utikal J, Udart M, Greulich K, Bezold G, Kaskel P . Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer. 2001; 84(1):72-9. PMC: 2363612. DOI: 10.1054/bjoc.2000.1535. View

14.

Ugurel S, Rappl G, Tilgen W, Reinhold U . Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001; 19(2):577-83. DOI: 10.1200/JCO.2001.19.2.577. View

15.

Stahlecker J, Gauger A, Bosserhoff A, Buttner R, Ring J, Hein R . MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 2001; 20(6D):5041-4. View

16.

Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D . Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001; 19(3):239-47. DOI: 10.1081/cnv-100102550. View

17.

Ugurel S, Rappl G, Tilgen W, Reinhold U . Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 2001; 7(5):1282-6. View

18.

Krahn G, Kaskel P, Sander S, Waizenhofer P, Wortmann S, Leiter U . S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001; 21(2B):1311-6. View

19.

Udart M, Utikal J, Krahn G, Peter R . Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia. 2001; 3(3):245-54. PMC: 1505589. DOI: 10.1038/sj.neo/7900156. View

20.

Balch C, Buzaid A, Soong S, Atkins M, Cascinelli N, Coit D . Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19(16):3635-48. DOI: 10.1200/JCO.2001.19.16.3635. View